AirSculpt Technologies Inc

In Stage 2 Advancing, AIRS retains a medium-term bullish bias underpinned by higher highs/lows and support at the rising 50 DMA, but short-term timing is neutral as price pulls back into the 9/21/50 EMA zone. Execution should be deferred around this support range, seeking evidence of acceptance before committing. Primary risk is a decisive break below the 50 DMA and prior higher-low, which would invalidate the bullish outlook.

• ↑GLP-1 meds could grow patient base from 5M to 25M by 2030, with 63% intent (~19M patients).
• ↑Q1 revenue $39.4M (+19% sequential; flat YoY) with same-center sales up 1%.
• ↓Negative earnings yield and significant revisions signal underlying operational weakness.